lundi 2 mars 2020

Onco Actu du 2 mars 2020


2. ETIOLOGIE



Genetic ‘fingerprints’ implicate gut bacterium in bowel cancer [University of Leeds]










Common toxin made in gut can cause bowel cancer, scientists find [The Guardian











3.3 PRÉVENTION - VACCINS



The High Risk Methods of a New Systematic Review of HPV Vaccines [Absolutely Maybe]










4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC



New Approach Uses Much Less Tissue to Analyze Tumor Proteins and Genes [NCI]











4.10 DÉP., DIAG. & PRONO. - POUMON



Screening for Lung Cancer — 10 States, 2017 [CDC]











Carl Heneghan and Jeffrey Aronson: Interpreting lung cancer screening studies [BMJ]










5.1 TRAITEMENTS - PRÉ-CLINIQUE



New chemo combo shows promise versus pancreatic cancer [Cornell]











5.10 TRAITEMENTS - ESSAIS



UC research: Under reporting of data on the outcomes among older adults in cancer clinical trials [University of Cincinnati]











5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS



Boehringer taps Trutino to bag safer, more efficacious cytokines [Fierce Biotech]











Boehringer Ingelheim Enters Discovery Stage Collaboration with Trutino Biosciences to Grow Its Cancer Immunology Portfolio with Novel Cytokine Platform [Boehringer Ingelheim]











5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE



NIH, Tuskegee Researchers Develop Potential New Type of Immunotherapy Across Cancers and Many Other Diseases [NIH]











High doses of vitamin C found to enhance immunotherapy in combating cancer in mice [Medical XPress]











Nanosize Device ‘Uncloaks’ Cancer Cells in Mice And Reveals Them to The Immune System [Johns Hopkins]










5.12.3 IMMUNOTHÉRAPIES-COMBINAISONS



Combined therapy may improve clinical responses for endometrial, colorectal and gastric tumors [MD Anderson Cancer Center]











5.2 PHARMA



Lilly's Cyramza wins narrow thumbs-up from FDA advisers for Tarceva combo in lung cancer [Fierce Pharma]











AbbVie Provides Update from Phase 3 Study Evaluating VENCLEXTA® (venetoclax) in Combination with Low-Dose Cytarabine in Newly-Diagnosed Patients with Acute Myeloid Leukemia (AML) [AbbVie]











5.2.2 PHARMA - FUSIONS & ACQUISITIONS



Gilead hungry for 'don't eat me' cancer biotech: reports [Fierce Biotech]











A name emerges out of the Gilead M&A rumor mill, and it’s a cancer biotech [EndPoints]











5.2.6 PHARMA - BIOTECH



FDA Grants Breakthrough Therapy Designation For Debiopharm’s Novel Chemo-Radio Sensitizer DEBIO 1143 For Front-Line Treatment Of Head & Neck Cancer [Debiopharm]











FDA taps chemoradio-sensitizing head and neck cancer drug as 'breakthrough' [EndPoints]











Turning focus to clinical work, Verastem axes 31 jobs, scales back cancer drug promotion after disappointing sales [EndPoints]











5.3 TRAITEMENTS - FDA, EMA,...



Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 February 2020 [EMA]











5.4.1 TRAITEMENTS - ECONOMIE - NICE



‘Chemotherapy-free’ treatment for lymphoma made available for NHS use in England [Cancer Research UK]











NICE recommends new ‘chemotherapy-free’ treatment for lymphoma [NICE]










UK follicular lymphoma patients set to get non-chemotherapy therapy as NICE backs Revlimid combo [EndPoints]











6.3 ASSOCIATIONS/FONDATIONS



New European Partnerships to Accelerate Cancer Research [Cancer Research UK]











6.7.1 IA/BIOINFORMATIQUE



Two Tribes [In The Pipeline]











6.7.3 DMP



To Measure The Burden Of EHR Use, Audit Logs Offer Promise—But Not Without Further Collaboration [Health Affairs]